Business context and reporting period
Filing identity: The supplied filing is GlycoMimetics, Inc.’s Form 10-Q for the quarter ended June 30, 2020—not a Crescent BioPharma filing. Investors should verify the company and filing before relying on this summary.
GlycoMimetics is a clinical-stage biotechnology company with no approved products or commercial drug sales. Its programs include uproleselan for acute myeloid leukemia (AML), GMI-1359, GMI-1687 and other preclinical candidates. The financial statements are unaudited.
Financial results and liquidity
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $9.0 million | $0 |
| Research and development | $9.9 million | $13.1 million | $22.5 million | $24.8 million |
| General and administrative | $4.2 million | $3.8 million | $8.7 million | $7.1 million |
| Operating loss | $14.1 million | $16.8 million | $22.2 million | $31.9 million |
| Net loss | $14.1 million | $15.8 million | $21.7 million | $29.9 million |
| Basic and diluted loss per share | $0.32 | $0.37 | $0.50 | $0.69 |
The $9.0 million first-half revenue was the non-refundable upfront payment under the Apollomics license, recognized in Q1. No product-sales revenue was reported. Gross margin is not meaningful given the absence of product sales and cost of sales.
At June 30, cash and cash equivalents were $149.8 million, down $8.4 million from year-end 2019. Current assets were $153.4 million and current liabilities $9.7 million. Total liabilities were $12.6 million, primarily accrued expenses and operating lease liabilities; the filing reports no borrowings or interest-bearing debt. First-half operating cash use was $18.1 million, investing cash use $0.015 million, and financing cash inflow $9.7 million. Stockholders’ equity was $145.8 million.
Changes versus comparable periods
- Q2 net loss narrowed by $1.8 million year over year; first-half net loss narrowed by $8.2 million, helped by the Apollomics upfront revenue and lower operating expenses.
- R&D expense fell 24% in Q2 and 9% for the first half. Lower manufacturing and formulation costs were partly offset by higher clinical development spending, including uproleselan trials.
- G&A expense rose 13% in Q2 and 22% for the first half, reflecting increased personnel-related costs and, for the first half, higher professional fees.
- Interest income decreased substantially: 97% in Q2 and 77% for the first half, attributed to lower cash balances and interest rates.
- Cash used in operations improved to $18.1 million from $25.7 million in the first half of 2019. The company also raised $9.6 million net through its at-the-market (ATM) stock facility, issuing 3.13 million shares in Q2 at a weighted-average $3.16 per share.
Outlook, commentary and risks
- Management estimated existing cash would fund operations into 2022, subject to assumptions and clinical-trial spending. Separately, the financial-statement note says funds are sufficient for at least 12 months from the filing date; investors should reconcile these runway statements.
- The company expected to complete enrollment in the global Phase 3 uproleselan trial in relapsed/refractory AML in the second half of 2021. COVID-19 slowed site initiation and enrollment in April 2020; enrollment later showed an upward trend, but further delays remained possible.
- In January 2020, GlycoMimetics licensed Greater China rights to uproleselan and GMI-1687 to Apollomics. The agreement provides up to $75 million in development milestones, up to $105 million in sales-based milestones, and tiered royalties from the high single digits to 15%; these payments are contingent and not assured.
- Pfizer terminated its rivipansel license effective April 2020 after the Phase 3 trial missed primary and key secondary endpoints, returning development and commercialization rights to GlycoMimetics. A later post hoc analysis reported a benefit for patients treated within approximately 26 hours of pain onset; the company planned to discuss possible next steps with FDA.
- Management expects continued operating losses and negative operating cash flows. Further funding may be needed; equity financing could dilute shareholders, and financing may be unavailable on acceptable terms. The ATM registration shelf was due to expire October 6, 2020. After quarter-end, the company sold 1.01 million additional shares for approximately $4.6 million net.
- Other material risks include clinical efficacy and regulatory uncertainty, trial enrollment and manufacturing dependencies, and COVID-related disruption to trial sites, supply chains and capital markets. The filing reported no material legal proceedings and no material changes to internal control over financial reporting.
Most important facts to verify
- Confirm the filing belongs to GlycoMimetics, Inc.; the request metadata names Crescent BioPharma, Inc.
- Reconcile the cash runway statements (“into 2022” in MD&A versus “at least 12 months from filing” in the notes).
- Track uproleselan Phase 3 enrollment, COVID-related effects and the stated second-half 2021 enrollment target.
- Assess the contingent value and development progress of the Apollomics license, and any FDA-directed next steps for rivipansel.
- Check subsequent ATM share issuance, dilution, remaining facility capacity and the shelf registration’s October 2020 expiration.